




# Collaborative



**Median BP:**  
128-134/77-82 mm Hg  
**MAP:** 96 mm Hg



**Methods:** Participants received either captopril 25 mg thrice daily or placebo plus standard treatment for a goal BP of  $< 140/90$  mm Hg or a 10-mm Hg reduction in SBP if baseline SBP was  $> 150$  mm Hg. Notably, those in the captopril arm had a lower urinary protein excretion rate at baseline.

**Results:** After a median of 3 years follow-up, mean arterial pressure (MAP) was reduced in the captopril group by approximately 4 mm Hg more than the placebo group. The risk of serum creatinine doubling was significantly reduced in patients receiving captopril compared with those taking placebo.



**Median BP:**  
129-136/80-84 mm Hg  
**MAP:** 100 mm Hg

